Half-year report · Q2
3034.TEDINET S100URNY
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥124.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥180.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥88.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥6.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥9.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥137.3bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥117.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥107.4bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥79.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥64.9bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥58.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥52.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥50.3bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥477m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥265m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥32.43 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.11 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.8 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥64m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.4bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥622m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥928m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥125.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥124.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥686m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥7.9bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥237m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥237m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥63m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥173m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥801m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥897m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥897m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥142m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥88.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥88.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥237m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 543
| Item | Context | Value | Unit |
|---|---|---|---|
| Filer name in japanese | FilingDateInstant | Original text (Japanese)クオールホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Qol Holdings Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | - | |
| Fund name in english | FilingDateInstant | - | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | - | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | - | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | - | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | - | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)株式会社メディパルホールディングス | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都中央区京橋三丁目1番1号 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社(信託口) | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都港区赤坂一丁目8番1号 赤坂インターシティAIR | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)クオールグループ従業員持株会 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都港区虎ノ門四丁目3番1号城山トラストタワー37階 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)中村 敬 | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都杉並区 | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)高橋 新 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)大阪府門真市 | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)MSIP CLIENT SECURITIES (常任代理人 モルガン・スタンレーMUFG証券株式会社) | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |